Key points
- Total revenue of US$120.3 million up from US$17.2 million in the prior year period.
- Successful U.S. commercial launch of Ryoncil generated net revenue of US$115.2 million.
- Completed 350 patients treated in the pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain.
Full summary
Mesoblast Limited, a global leader in allogeneic cellular medicines, reported financial results and an operational update for the full year ended June 30, 2026. The company achieved a total revenue of US$120.3 million, significantly up from US$17.2 million in the prior year period. The success was primarily due to the U.S. commercial launch of Ryoncil, which generated net revenue of US$115.2 million. The company also completed the treatment phase of a pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain, involving 350 patients. Mesoblast is now focusing on expanding Ryoncil use to adults with severe steroid-refractory acute graft versus host disease and is preparing for a potential multi-billion-dollar market opportunity with the upcoming readout of the chronic low back pain trial.
Guidance
Total revenue of US$120.3 million for FY2026
Outlook
Mesoblast plans to expand Ryoncil use to adults with severe steroid-refractory acute graft versus host disease and anticipates a potential multi-billion-dollar market opportunity with the upcoming readout of the chronic low back pain trial.